As of 2026-04-28, the Relative Valuation of Halozyme Therapeutics Inc (HALO) is 72.54 USD. This relative valuation is based on P/E multiples. With the latest stock price at 64.49 USD, the upside of Halozyme Therapeutics Inc based on Relative Valuation is 12.5%.
The range of the Relative Valuation is 60.88 - 98.23 USD.
| Range | Selected | |
| Trailing P/E multiples | 22.8x - 24.8x | 24.0x |
| Forward P/E multiples | 20.9x - 29.0x | 24.0x |
| Fair Price | 60.88 - 98.23 | 72.54 |
| Upside | -5.6% - 52.3% | 12.5% |
| Date | P/E |
| 2026-04-24 | 24.44 |
| 2026-04-23 | 24.89 |
| 2026-04-22 | 25.57 |
| 2026-04-21 | 25.58 |
| 2026-04-20 | 26.01 |
| 2026-04-17 | 25.90 |
| 2026-04-16 | 24.91 |
| 2026-04-15 | 25.44 |
| 2026-04-14 | 25.16 |
| 2026-04-13 | 25.04 |
| 2026-04-10 | 25.35 |
| 2026-04-09 | 25.08 |
| 2026-04-08 | 24.46 |
| 2026-04-07 | 23.78 |
| 2026-04-06 | 23.58 |
| 2026-04-02 | 24.11 |
| 2026-04-01 | 24.45 |
| 2026-03-31 | 24.16 |
| 2026-03-30 | 23.23 |
| 2026-03-27 | 23.04 |
| 2026-03-26 | 23.66 |
| 2026-03-25 | 23.64 |
| 2026-03-24 | 23.19 |
| 2026-03-23 | 23.50 |
| 2026-03-20 | 23.71 |
| 2026-03-19 | 23.65 |
| 2026-03-18 | 23.80 |
| 2026-03-17 | 24.35 |
| 2026-03-16 | 24.04 |
| 2026-03-13 | 23.80 |
| 2026-03-12 | 23.76 |
| 2026-03-11 | 24.85 |
| 2026-03-10 | 25.35 |
| 2026-03-09 | 25.47 |
| 2026-03-06 | 25.19 |
| 2026-03-05 | 25.18 |
| 2026-03-04 | 26.18 |
| 2026-03-03 | 25.95 |
| 2026-03-02 | 26.11 |
| 2026-02-27 | 25.99 |
| 2026-02-26 | 25.88 |
| 2026-02-25 | 26.30 |
| 2026-02-24 | 26.30 |
| 2026-02-23 | 26.41 |
| 2026-02-20 | 26.54 |
| 2026-02-19 | 26.93 |
| 2026-02-18 | 27.38 |
| 2026-02-17 | 30.09 |
| 2026-02-13 | 29.70 |
| 2026-02-12 | 28.76 |